Establishment of Pulmonary Fibrosis Mouse Model
Clinical Assessment of Pulmonary Fibrosis Mouse Model based on C57BL/6 mice. Values are expressed as mean ± SEM. *** p<0.001,
Efficacy Validation on Pulmonary Fibrosis model (B-hCCN2 mice ) for Pamrevlumab
Pamrevlumab treatment was able to improve bleomycin-induced weight loss in B-hCCN2 mice and Pamrevlumab is effective in reducing mortality from Bleomycin.
Bleomycin treatment increases HYP content compared with controls. Compared with vehicle-treated bleomycin controls, pamrevlumab treatment resulted in a reduction in mean induced lung HYP content . Values are expressed as mean ± SEM. *** p<0.001, **p<0.01.